Mary Elizabeth Hartnett

Mary Elizabeth Hartnett, MD

Languages spoken: English

Academic Information

Departments Adjunct - Ophthalmology & Visual Sciences , Adjunct - Pediatrics

Academic Office Information

ME.Hartnett@hsc.utah.edu

Board Certification

  • American Board of Ophthalmology

Mary Elizabeth Hartnett, MD, holds the Calvin S. and JeNeal N. Hatch Presidential Endowed Chair in Ophthalmology and Visual Sciences and is a Distinguished Professor at the University of Utah. She is an adjunct professor at the University of Utah departments of Neurobiology and Pediatrics. Dr. Hartnett is the founder and director of Pediatric Retina at the John A. Moran Eye Center and principal investigator of the Retinal Angiogenesis Laboratory.

As director of Moran's Pediatric Retina Center, Dr. Hartnett is one of a few pediatric retina specialists internationally trained to diagnose and treat pediatric retina disorders, which disrupt the healthy development of the light-sensitive tissue at the back of the eye. She also practices as a vitreoretinal surgeon, providing treatment to patients throughout the Mountain West. She performs surgery at the Moran Eye Center and Primary Children's Hospital.

Her mission is to deliver the best possible care and education while conducting critical research to make future advances in pediatric retina care.

She created the first-ever academic textbook on the subject, Pediatric Retina, in its third edition, which has proven to be an invaluable resource for residents and ophthalmologists internationally. She is a co-director of the Advances in Pediatric Retina meeting held every two years, most recently in 2019 at the U.

Dr. Hartnett has received numerous awards, including the Weisenfeld Award, the highest award for clinician-scientists given by the Association for Research in Vision and Ophthalmology (ARVO), in 2018. She received the 2019 Paul Kayser/Retina Research Foundation Global Award, the Macula Society’s 2016 Paul Henkind Award and its 2019 Arnall Patz Medal, and the 2021 Suzanne Veronneau-Troutman Award, the most prestigious award from Women in Ophthalmology. In 2022, she will receive the Gertrude Pyron award, the highest award from the American Association of Retina Specialists. She was one of six at the University of Utah to receive a distinguished research award, for Pediatrics and Ophthalmology.

Dr. Hartnett's prolific publication record includes more than 225 articles in peer-reviewed journals and over 40 book chapters. She has delivered numerous national and international invited lectures. Her long list of professional committee work includes serving as chair of the Publications Committee of ARVO, as a mentor for the ARVO Leadership Development Program, and in leadership positions internationally as chair of the research advisory committees for The Macula Society and the Jack McGovern Coats Disease Foundation as well as Chair of the Credentialing Committee for The Retina Society. She reviews manuscripts for more than 20 eye and science journals and serves on the editorial boards of PlosOne, Molecular Vision, and the American Journal of Ophthalmology. Dr. Hartnett is a Fellow of the American College of Surgeons (FACS) and a Silver and Gold Fellow of the Association for Research in Vision and Ophthalmology (FARVO).

Education History

Post Graduate Training Children’s Hospital and Schepens Eye Research Institute, Harvard University
 Postgraduate Studies
Schepens Retina Associates, Massachusetts Eye and Ear Infirmary, Harvard Medical School
 Fellow
Research Fellow Harvard University
 Research Fellow
Schepens Retina Associates
 Chief Fellow
Fellowship Massachusetts Eye and Ear Infirmary, Harvard Medical School, Schepens Retina Associates
 Fellow
Schepens Eye Research Institute, Harvard Medical School
 Research Fellow
Residency University Hospitals of Cleveland, VA Medical Center
 Resident
University Hospitals of Cleveland
 Intern
Other Training St. Peter's Hospital
Albany Medical College
 MD
Undergraduate Rensselaer Polytechnic Institute
 BS

Selected Publications

Journal Article

  1. Wang H, Ramshekar A, Kunz E, Hartnett ME (2021). 7-ketocholesterol induces endothelial-mesenchymal transition and promotes fibrosis: implications in neovascular age-related macular degeneration and treatment. Angiogenesis, 24(3), 583-595. (Read full article)
  2. Ramshekar A, Wang H, Kunz E, Pappas C, Hageman GS, Chaqour B, Sacks DB, Hartnett ME (2021). Active Rap1-mediated inhibition of choroidal neovascularization requires interactions with IQGAP1 in choroidal endothelial cells. FASEB J, 35(7), e21642. (Read full article)
  3. Spaide RF, Gemmy Cheung CM, Matsumoto H, Kishi S, Boon CJF, van Dijk EHC, Mauget-Faysse M, Behar-Cohen F, Hartnett ME, Sivaprasad S, Iida T, Brown DM, Chhablani J, Maloca PM (2021). Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res, 100973. (Read full article)
  4. Pivodic A, Johansson H, Smith LEH, Hrd AL, Lfqvist C, Yoder BA, Hartnett ME, Wu C, Brnder MC, Lagrze WA, Stahl A, Al-Hawasi A, Larsson E, Lundgren P, Grnse L, Sunnqvist B, Tornqvist K, Wallin A, Holmstrm G, Albertsson-Wikland K, Nilsson S, Hellstrm A (2021). Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity. Br J Ophthalmol, 106(11), 1573-1580. (Read full article)
  5. Stagg BC, Stein JD, Medeiros FA, Wirostko B, Crandall A, Hartnett ME, Cummins M, Morris A, Hess R, Kawamoto K (2020). Special Commentary: Using Clinical Decision Support Systems to Bring Predictive Models to the Glaucoma Clinic. Ophthalmol Glaucoma, 4(1), 5-9. (Read full article)
  6. Hicks PM, Haaland B, Feehan M, Crandall AS, Pettey JH, Nuttall E, Self W, Hartnett ME, Bernstein P, Vitale A, Shakoor A, Shulman JP, Sieminski SF, Kim I, Owen LA, Murtaugh MA, Noyes A, DeAngelis MM (2020). Systemic Disease and Ocular Comorbidity Analysis of Geographically Isolated Federally Recognized American Indian Tribes of the Intermountain West. J Clin Med, 9(11). (Read full article)
  7. Hartnett ME (2020). Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor. Am J Ophthalmol, 218, 208-213. (Read full article)
  8. Thornburg CD, Erickson SW, Page GP, Clark EAS, DeAngelis MM, Hartnett ME, Goldstein RF, Dagle JM, Murray JC, Poindexter BB, Das A, Cotten CM (2020). Correction: Genetic predictors of severe intraventricular hemorrhage in extremely low-birthweight infants. J Perinatol.
  9. Levine ES, Custo Greig E, Mendona LSM, Gulati S, Despotovic IN, Alibhai AY, Moult E, Muakkassa N, Quaranta-El Maftouhi M, El Maftouhi A, Chakravarthy U, Fujimoto JG, Baumal CR, Witkin AJ, Duker JS, Hartnett ME, Waheed NK (2020). The long-term effects of anti-vascular endothelial growth factor therapy on the optical coherence tomography angiographic appearance of neovascularization in age-related macular degeneration. Int J Retina Vitreous, 6, 39. (Read full article)
  10. Bretz CA, Ramshekar A, Kunz E, Wang H, Hartnett ME (2020). Signaling Through the Erythropoietin Receptor Affects Angiogenesis in Retinovascular Disease. Invest Ophthalmol Vis Sci, 61(10), 23. (Read full article)
  11. Hamad AE, Moinuddin O, Blair MP, Schechet SA, Shapiro MJ, Quiram PA, Mammo DA, Berrocal AM, Prakhunhungsit S, Cernichiaro-Espinosa LA, Mukai S, Yonekawa Y, Ung C, Holz ER, Harper CA 3rd, Young RC, Besirli CG, Nagiel A, Lee TC, Gupta MP, Walsh MK, Khawly JA, Campbell JP, Kychenthal A, Nudleman ED, Robinson JE, Hartnett ME, Calvo CM, Chang EY (2019). Late-Onset Retinal Findings and Complications in Untreated Retinopathy of Prematurity. Ophthalmol Retina, 4(6), 602-612. (Read full article)
  12. Global Retinoblastoma Study Group, Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Adamou Boubacar S, Ademola-Popoola DS, Adio A, Afshar AR, Aggarwal P, Aghaji AE, Ahmad A, Akib MNR, Al Harby L, Al Ani MH, Alakbarova A, Portabella SA, Al-Badri SAF, Alcasabas APA, Al-Dahmash SA, Alejos A, Alemany-Rubio E, Alfa Bio AI, Alfonso Carreras Y, Al-Haddad C, Al-Hussaini HHY, Ali AM, Alia DB, Al-Jadiry MF, Al-Jumaily U, Alkatan HM, All-Eriksson C, Al-Mafrachi AARM, Almeida AA, Alsawidi KM, Al-Shaheen AASM, Al-Shammary EH, Amiruddin PO, Antonino R, Astbury NJ, Atalay HT, Atchaneeyasakul LO, Atsiaya R, Attaseth T, Aung TH, Ayala S, Baizakova B, Balaguer J, Balayeva R, Balwierz W, Barranco H, Bascaran C, Beck Popovic M, Benavides R, Benmiloud S, Bennani Guebessi N, Berete RC, Berry JL, Bhaduri A, Bhat S, Biddulph SJ, Biewald EM, Bobrova N, Boehme M, Boldt HC, Bonanomi MTBC, Bornfeld N, Bouda GC, Bouguila H, Boumedane A, Brennan RC, Brichard BG, Buaboonnam J, Caldern-Sotelo P, Calle Jara DA, Camuglia JE, Cano MR, Capra M, Cassoux N, Castela G, Castillo L, Catal-Mora J, Chantada GL, Chaudhry S, Chaugule SS, Chauhan A, Chawla B, Chernodrinska VS, Chiwanga FS, Chuluunbat T, Cieslik K, Cockcroft RL, Comsa C, Correa ZM, Correa Llano MG, Corson TW, Cowan-Lyn KE, Cska M, Cui X, Da Gama IV, Dangboon W, Das A, Das S, Davanzo JM, Davidson A, De Potter P, Delgado KQ, Demirci H, Desjardins L, Diaz Coronado RY, Dimaras H, Dodgshun AJ, Donaldson C, Donato Macedo CR, Dragomir MD, Du Y, Du Bruyn M, Edison KS, Eka Sutyawan IW, El Kettani A, Elbahi AM, Elder JE, Elgalaly D, Elhaddad AM, Elhassan MMA, Elzembely MM, Essuman VA, Evina TGA, Fadoo Z, Fandio AC, Faranoush M, Fasina O, Fernndez DDPG, Fernndez-Teijeiro A, Foster A, Frenkel S, Fu LD, Fuentes-Alabi SL, Gallie BL, Gandiwa M, Garcia JL, Garca Aldana D, Gassant PY, Geel JA, Ghassemi F, Girn AV, Gizachew Z, Goenz MA, Gold AS, Goldberg-Lavid M, Gole GA, Gomel N, Gonzalez E, Gonzalez Perez G, Gonzlez-Rodrguez L, Garcia Pacheco HN, Graells J, Green L, Gregersen PA, Grigorovski NDAK, Guedenon KM, Gunasekera DS, Gndz AK, Gupta H, Gupta S, Hadjistilianou T, Hamel P, Hamid SA, Hamzah N, Hansen ED, Harbour JW, Hartnett ME, Hasanreisoglu M, Hassan S, Hassan S, Hederova S, Hernandez J, Hernandez LMC, Hessissen L, Hordofa DF, Huang LC, Hubbard GB, Hummlen M, Husakova K, Hussein Al-Janabi AN, Ida R, Ilic VR, Jairaj V, Jeeva I, Jenkinson H, Ji X, Jo DH, Johnson KP, Johnson WJ, Jones MM, Kabesha TBA, Kabore RL, Kaliki S, Kalinaki A, Kantar M, Kao LY, Kardava T, Kebudi R, Kepak T, Keren-Froim N, Khan ZJ, Khaqan HA, Khauv P, Kheir WJ, Khetan V, Khodabande A, Khotenashvili Z, Kim JW, Kim JH, Kiratli H, Kivel TT, Klett A, Komba Palet JEK, Krivaitiene D, Kruger M, Kulvichit K, Kuntorini MW, Kyara A, Lachmann ES, Lam CPS, Lam GC, Larson SA, Latinovic S, Laurenti KD, Le BHA, Lecuona K, Leverant AA, Li C, Limbu B, Long QB, Lpez JP, Lukamba RM, Lumbroso L, Luna-Fineman S, Lutfi D, Lysytsia L, Magrath GN, Mahajan A, Majeed AR, Maka E, Makan M, Makimbetov EK, Manda C, Martn Begue N, Mason L, Mason JO 3rd, Matende IO, Materin M, Mattosinho CCDS, Matua M, Mayet I, Mbumba FB, McKenzie JD, Medina-Sanson A, Mehrvar A, Mengesha AA, Menon V, Mercado GJVD, Mets MB, Midena E, Mishra DKC, Mndeme FG, Mohamedani AA, Mohammad MT, Moll AC, Montero MM, Morales RA, Moreira C, Mruthyunjaya P, Msina MS, Msukwa G, Mudaliar SS, Muma KI, Munier FL, Murgoi G, Murray TG, Musa KO, Mushtaq A, Mustak H, Muyen OM, Naidu G, Nair AG, Naumenko L, Ndoye Roth PA, Nency YM, Neroev V, Ngo H, Nieves RM, Nikitovic M, Nkanga ED, Nkumbe H, Nuruddin M, Nyaywa M, Obono-Obiang G, Oguego NC, Olechowski A, Oliver SCN, Osei-Bonsu P, Ossandon D, Paez-Escamilla MA, Pagarra H, Painter SL, Paintsil V, Paiva L, Pal BP, Palanivelu MS, Papyan R, Parrozzani R, Parulekar M, Pascual Morales CR, Paton KE, Pawinska-Wasikowska K, Peer J, Pea A, Peric S, Pham CTM, Philbert R, Plager DA, Pochop P, Polania RA, Polyakov VG, Pompe MT, Pons JJ, Prat D, P (2020). Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA Oncol, 6(5), 685-695. (Read full article)
  13. Bretz CA, Simmons AB, Kunz E, Ramshekar A, Kennedy C, Cardenas I, Hartnett ME (2020). Erythropoietin Receptor Signaling Supports Retinal Function after Vascular Injury. Am J Pathol, 190(3), 630-641. (Read full article)
  14. Wang H, Kunz E, Stoddard GJ, Hauswirth WW, Hartnett ME (2019). Optimal Inhibition of Choroidal Neovascularization by scAAV2 with VMD2 Promoter-driven Active Rap1a in the RPE. Sci Rep, 9(1), 15732. (Read full article)
  15. Mastey RR, Georgiou M, Langlo CS, Kalitzeos A, Patterson EJ, Kane T, Singh N, Vincent A, Moore AT, Tsang SH, Lin JH, Young MP, Hartnett ME, Hon E, Kohl S, Michaelides M, Carroll J (2019). Characterization of Retinal Structure in ATF6-Associated Achromatopsia. Invest Ophthalmol Vis Sci, 60(7), 2631-2640. (Read full article)
  16. Hartnett ME, Toth CA (2019). Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retina, 50(4), 228-234. (Read full article)
  17. Jeng-Miller KW, Soomro T, Scott NL, Rao P, Marlow E, Chang EY, Ells A, Chau F, Nudleman E, Calvo CM, Patel N, Schwartz R, Cernichiaro-Espinosa LA, Montoya AG, Goldstein J, Harper CA 3rd, Baumal CR, Hartnett ME, Harbour JW, Besirli CG, Gupta MP, Chan RVP, Drenser KA, Capone A Jr, Murray TG, Mukai S, Trese MT, Berrocal AM, Wong SC, Yonekawa Y (2019). Longitudinal Examination of Fellow-Eye Vascular Anomalies in Coats' Disease With Widefield Fluorescein Angiography: A Multicenter Study. Ophthalmic Surg Lasers Imaging Retina, 50(4), 221-227. (Read full article)
  18. Mangalesh S, Bleicher ID, Chen X, Viehland C, LaRocca F, Izatt JA, Freedman SF, Hartnett ME, Toth CA (2019). Three-dimensional pattern of extraretinal neovascular development in retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol, 257(4), 677-688. (Read full article)
  19. Hartnett ME (2019). Discovering Mechanisms in the Changing and Diverse Pathology of Retinopathy of Prematurity: The Weisenfeld Award Lecture. Invest Ophthalmol Vis Sci, 60(5), 1286-1297. (Read full article)
  20. Han X, Kong J, Hartnett ME, Wang H (2019). Enhancing Retinal Endothelial Glycolysis by Inhibiting UCP2 Promotes Physiologic Retinal Vascular Development in a Model of Retinopathy of Prematurity. Invest Ophthalmol Vis Sci, 60(5), 1604-1613. (Read full article)
  21. Hicks PM, Melendez SAC, Vitale A, Self W, Hartnett ME, Bernstein P, Morgan DJ, Feehan M, Shakoor A, Kim I, Owen LA, DeAngelis MM (2019). Genetic Epidemiologic Analysis of Hypertensive Retinopathy in an Underrepresented and Rare Federally Recognized Native American Population of the Intermountain West. J Community Med Public Health, 3(1). (Read full article)
  22. Hansen ED, Hartnett ME (2019). A review of treatment for retinopathy of prematurity. Expert Rev Ophthalmol, 14(2), 73-87. (Read full article)
  23. Greene T, Hartnett ME (2018). Programming Error Led to Underestimate of Effect Sizes in Study of Association of Maternal Preeclampsia and Risk of Infant Retinopathy of Prematurity. JAMA Ophthalmol, 137(1), 119. (Read full article)
  24. Yarishkin O, Phuong TTT, Bretz CA, Olsen KW, Baumann JM, Lakk M, Crandall A, Heurteaux C, Hartnett ME, Kriaj D (2018). TREK-1 channels regulate pressure sensitivity and calcium signaling in trabecular meshwork cells. J Gen Physiol, 150(12), 1660-1675. (Read full article)
  25. Simmons MA, Cheng AV, Becker S, Gerkin RD, Hartnett ME (2018). Automatic analysis of the retinal avascular area in the rat oxygen-induced retinopathy model. Mol Vis, 24, 767-777. (Read full article)
  26. Shulman JP, Hartnett ME (2018). Corrigendum: Pharmacotherapy and ROP: Going Back to the Basics. Asia Pac J Ophthalmol (Phila), 7(5), 365. (Read full article)
  27. Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, Hartnett ME, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NL, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber RG (2018). Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. JAMA Ophthalmol, 136(8), 849-856. (Read full article)
  28. Zayed MA, Uppal A, Hartnett ME (2010). New-onset maternal gestational hypertension and risk of retinopathy of prematurity. Invest Ophthalmol Vis Sci, 51(10), 4983-8. (Read full article)
  29. Sleath B, Blalock SJ, Robin A, Hartnett ME, Covert D, DeVellis B, Giangiacomo A (2010). Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations. Eye (Lond), 24(4), 624-31. (Read full article)
  30. Budd SJ, Hartnett ME (2010). Increased Angiogenic Compounds during Persistent Avascular Retina in a Model of ROP. Arch Ophthalmol, 128(8), 1014-21.
  31. Hartnett ME, Tinkham N, Paynter L, Geisen P, Rosenberg P, Koch G, Cohen KL (2009). Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus. Am J Ophthalmol, 148(6), 895-901.e1. (Read full article)
  32. Budd S, Byfield G, Martiniuk D, Geisen P, Hartnett ME (2009). Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP. Exp Eye Res, 89(5), 718-27. (Read full article)
  33. Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, Kaneko H, Albuquerque RJ, Dridi S, Saito K, Raisler BJ, Budd SJ, Geisen P, Munitz A, Ambati BK, Green MG, Ishibashi T, Wright JD, Humbles AA, Gerard CJ, Ogura Y, Pan Y, Smith JR, Grisanti S, Hartnett ME, Rothenberg ME, Ambati J (2009). CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature, 460(7252), 225-30. (Read full article)
  34. Byfield G, Budd S, Hartnett ME (2009). The role of supplemental oxygen and JAK/STAT signaling in intravitreous neovascularization in a ROP rat model. Invest Ophthalmol Vis Sci, 50(7), 3360-5. (Read full article)
  35. Scott IU, Blodi BA, Ip MS, Vanveldhuisen PC, Oden NL, Chan CK, Gonzalez V (2009). SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type. Ophthalmology, 116(4), 756-61. (Read full article)
  36. Ulmasov B, Bruno J, Gordon N, Hartnett ME, Edwards JC (2009). Chloride intracellular channel protein-4 functions in angiogenesis by supporting acidification of vacuoles along the intracellular tubulogenic pathway. Am J Pathol, 174(3), 1084-96. (Read full article)
  37. Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C (2009). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol, 127(3), 245-51. (Read full article)
  38. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa M (2009). SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology, 116(3), 504-12. (Read full article)
  39. Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, Elman MJ, Glassman AR, Gross JG, Kollman C, Wells JA 3rd (2009). Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol, 127(2), 132-40. (Read full article)
  40. Reynolds R, Hartnett ME, Rosner B, Atkinson J, Giclas PC, Seddon JM (2009). Plasma Complement Components and Activation Fragments are Associated with Age-Related Macular Degeneration Genotypes and Phenotypes. Invest Ophthalmol Vis Sci.
  41. Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H (2008). Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology, 115(8), 1366-71, 1371.e1. (Read full article)
  42. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME (2008). Vascular endothelial growth factor in eye disease. Prog Retin Eye Res, 27(4), 331-71. (Read full article)
  43. Hartnett ME, Martiniuk D, Byfield G, Geisen P, Zeng G, Bautch VL (2008). Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease. Invest Ophthalmol Vis Sci, 49(7), 3107-14. (Read full article)
  44. Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H (2008). A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina, 28(7), 919-30. (Read full article)
  45. Davis MD, Bressler SB, Aiello LP, Bressler NM, Browning DJ, Flaxel CJ, Fong DS, Foster WJ, Glassman AR, Hartnett ME, Kollman C, Li HK, Qin H, Scott IU (2008). Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci, 49(5), 1745-52. (Read full article)
  46. Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Sun JK (2008). Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol, 145(5), 894-901. (Read full article)
  47. Saito Y, Uppal A, Byfield G, Budd S, Hartnett ME (2008). Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model. Invest Ophthalmol Vis Sci, 49(4), 1591-8. (Read full article)
  48. Hartnett ME, Board RJ, Houghton O (2008). Subretinal hemorrhage after lens-sparing vitrectomy in infants born at or under 24 weeks gestation. Retina, 28(3 Suppl), S69-74. (Read full article)
  49. Vinekar A, Trese MT, Capone A Jr (2008). Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach. Am J Ophthalmol, 145(3), 548-555. (Read full article)
  50. Geisen P, Peterson LJ, Martiniuk D, Uppal A, Saito Y, Hartnett ME (2008). Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. Mol Vis, 14, 345-57. (Read full article)
  51. Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C, Qin H (2008). Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Retina, 28(1), 36-40. (Read full article)
  52. Diabetic Retinopathy Clinical Research Network (2008). A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology, 115, 1445-1456.
  53. Writing Committee for The Photographic Screening for Retinopathy of Prematurity Study Photo- ROP (2008). Primary Outcomes Ophthalmology. Retina, 28, S47-S54.
  54. Jacobson MA, Tan QX, Girling V, Poon C, Van Natta M, Jabs DA, Inokuma M, Maecker HT, Bredt B, and Sinclair E, for the Studies of Ocular Complications of AIDS Research Group (2008). Poor predictive value of cytomegalovirus (CMV)-Specific T cell assays for the development of CMV retinitis in patients with AIDS. Clin Infect Dis, 46, 458-466.
  55. Zayed MA, Yuan W, Leisner TM, Chalothorn D, McFadden AW, Schaller MD, Hartnett ME, Faber JE, Parise LV (2007). CIB1 regulates endothelial cells and ischemia-induced pathological and adaptive angiogenesis. Circ Res, 101(11), 1185-93. (Read full article)
  56. Bhavsar AR, Ip MS, Glassman AR (2007). The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol, 144(3), 454-6. (Read full article)
  57. Diabetic Retinopathy Clinical Research Network (2007). Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology, 114(8), 1520-5.
  58. Saito Y, Geisen P, Uppal A, Hartnett ME (2007). Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. Mol Vis, 13, 840-53. (Read full article)
  59. Peterson LJ, Wittchen ES, Geisen P, Burridge K, Hartnett ME (2007). Heterotypic RPE-choroidal endothelial cell contact increases choroidal endothelial cell transmigration via PI 3-kinase and Rac1. Exp Eye Res, 84(4), 737-44. (Read full article)
  60. Diabetic Retinopathy Clinical Research Network (2007). Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol, 125(4), 469-80.
  61. Diabetic Retinopathy Clinical Research Network (2007). Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology, 114(3), 525-36.
  62. Zeng G, Taylor SM, McColm JR, Kappas NC, Kearney JB, Williams LH, Hartnett ME, Bautch VL (2007). Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. Blood, 109(4), 1345-52. (Read full article)
  63. Steering Committee of Diabetic Retinopathy Clinical Research Network (2007). A phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology, 114, 1860-1867.
  64. Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD, for the Studies of Ocular Complications of AIDS Research Group (2007). Longitudinal Study of the Ocular Complications of AIDS. 1. Ocular diagnoses at enrollment. Ophthalmology, 114, 780-786.
  65. Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD, for the Studies of Ocular Complications of AIDS Research Group (2007). Longitudinal Study of the Ocular Complications of AIDS. 2. Ocular examination results at enrollment. Ophthalmology, 114, 787-793.
  66. Diabetic Retinopathy Clinical Research Network (2006). Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. Arch Ophthalmol, 124(12), 1701-7.
  67. Hartnett ME, Martiniuk DJ, Saito Y, Geisen P, Peterson LJ, McColm JR (2006). Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci, 47(11), 4975-82. (Read full article)
  68. Geisen P, McColm JR, King BM, Hartnett ME (2006). Characterization of barrier properties and inducible VEGF expression of several types of retinal pigment epithelium in medium-term culture. Curr Eye Res, 31(9), 739-48. (Read full article)
  69. Balasubramanian M, Capone A Jr, Hartnett ME, Pignatto S, Trese MT (2006). The Photographic Screening for Retinopathy of Prematurity Study (Photo-ROP): study design and baseline characteristics of enrolled patients. Retina, 26(7 Suppl), S4-10. (Read full article)
  70. Hartnett ME, McColm JR (2006). Fibrovascular organization in the vitreous following laser for ROP: implications for prognosis. Retina, 26(7 Suppl), S24-31. (Read full article)
  71. McColm JR, Geisen P, Peterson LJ, Hartnett ME (2006). Exogenous leukemia inhibitory factor (LIF) attenuates retinal vascularization reducing cell proliferation not apoptosis. Exp Eye Res, 83(2), 438-46. (Read full article)
  72. Escaravage GK Jr, Cohen KL, Patel SB, Hartnett ME, Armstrong BD, Janowski CM (2006). Quantification of macular and optic disc hyperfluorescence after phacoemulsification in diabetes mellitus. J Cataract Refract Surg, 32(5), 803-11. (Read full article)
  73. Geisen P, McColm JR, Hartnett ME (2006). Choroidal endothelial cells transmigrate across the retinal pigment epithelium but do not proliferate in response to soluble vascular endothelial growth factor. Exp Eye Res, 82(4), 608-19. (Read full article)
  74. PKC-DRS2 Group PI for LSU site (2006). Effect of Ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology, 113, 2221-2230.
  75. Thorne JE, Jabs DA, Kempen JH, Holbrook JT, Nichols C, Meinert CL, for the Studies of Ocular Complications of AIDS Research Group (2006). Causes of Visual Acuity Loss Among Patients with AIDS and Cytomegalovirus in the Era of Highly Active Antiretroviral Therapy. Ophthalmology, 113, 1441-1445.
  76. Kempen JH, Min Y-I, Freeman WR, Holland GN, Friedberg DN, Dieterich DT, Jabs DA for the Studies of Ocular Complications of AIDS Research Group (2006). Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology, 113, 684-694.
  77. Hartnett ME, Key IJ, Loyacano NM, Horswell RL, Desalvo KB (2005). Perceived barriers to diabetic eye care: qualitative study of patients and physicians. Arch Ophthalmol, 123(3), 387-91. (Read full article)
  78. Hartnett ME, Maguluri S, Thompson HW, McColm JR (2004). Comparison of retinal outcomes after scleral buckle or lens-sparing vitrectomy for stage 4 retinopathy of prematurity. Retina, 24(5), 753-7. (Read full article)
  79. McColm JR, Geisen P, Hartnett ME (2004). VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis, 10, 512-20. (Read full article)
  80. Van Cott EM, Laposata M, Hartnett ME (2004). Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis. Blood Coagul Fibrinolysis, 15(5), 393-7. (Read full article)
  81. Hartnett ME, McColm JR (2004). Retinal features predictive of progressive stage 4 retinopathy of prematurity. Retina, 24(2), 237-41. (Read full article)
  82. Jacobson MA, Maecker HT, Orr PL, DAmico R, Van Natta M, Li XD Pollard RB, Bredt BM for the Adult AIDS Clinical Trials Group and the Studies of Ocular Complications of AIDS Research Group (2004). Results of a CMV-specific CD8+/IFNy+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in AIDS patients with CMV retinitis. J Infect Dis, 189, 1362-1373.
  83. Jabs DA, Van Natta ML, Thorne JE, Weinberg DV, Meredith TA, Kuppermann BD, Sepkowitz K, Li HK for the Studies of Ocular Complications of AIDS Research Group (2004). Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology, 111, 2232-2239.
  84. Marshall BC, Jacobson MA, Adler SP in collaboration with the Studies of Ocular Complications of AIDS Research Group (2004). Avidity of antibodies to cytomegalovirus in HIV-seropositive patients with and without CMV retinitis. Viral Immunol, 17, 101-108.
  85. Hartnett ME, Lappas A, Darland D, McColm JR, Lovejoy S, DAmore PA (2003). Retinal pigment epithelium and endothelial cell interaction causes retinal pigment epithelial barrier dysfunction via a soluble VEGF-dependent mechanism. Exp Eye Res, 77(5), 593-9. (Read full article)
  86. Maguluri S, Hartnett ME (2003). Radial choroidal ruptures in sclopetaria. J Am Coll Surg, 197(4), 689-90. (Read full article)
  87. Hartnett ME, Rodier DW, McColm JR, Thompson HW (2003). Long-term vision results measured with Teller Acuity Cards and a new Light Perception/Projection Scale after management of late stages of retinopathy of prematurity. Arch Ophthalmol, 121(7), 991-6. (Read full article)
  88. Hartnett ME (2003). Features associated with surgical outcome in patients with stages 4 and 5 retinopathy of prematurity. Retina, 23(3), 322-9. (Read full article)
  89. Hartnett ME, Laposata M, Van Cott E (2003). Antiphospholipid antibody syndrome in a six-year-old female patient. Am J Ophthalmol, 135(4), 542-4. (Read full article)
  90. Kempen JH, Martin BK, Wu A, Barron B, Thorne JE, Jabs DA for the Studies of Ocular Complications of AIDS Research Group (2003). The effect of cytomegalovirus retinitis on the quality of life of patients with acquired immune deficiency syndrome in the era of highly active anti-retroviral therapy. Ophthalmology, 110, 987-995.
  91. Holbrook JT, Jabs DA, Weinberg DV, Lewis RA, Davis MD, Friedberg D for the Studies of Ocular Complications of AIDS Research Group (2003). Visual loss in patients with cytomegalovirus retinitis and AIDS before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol, 121(1), 99-107.
  92. Miura M, Elsner AE, Beausencourt E, Kunze C, Hartnett ME, Lashkari K, Trempe CL (2002). Grading of infrared confocal scanning laser tomography and video displays of digitized color slides in exudative age-related macular degeneration. Retina, 22(3), 300-8. (Read full article)
  93. Hartnett ME, Stratton RD, Browne RW, Rosner BA, Lanham RJ, Armstrong D (2000). Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care, 23(2), 234-40. (Read full article)
  94. Beausencourt E, Remky A, Elsner AE, Hartnett ME, Trempe CL (2000). Infrared scanning laser tomography of macular cysts. Ophthalmology, 107(2), 375-85. (Read full article)
  95. The STOP-ROP Multicenter Study Group (2000). Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), A randomized, controlled trial. I: Primary Outcomes. Pediatrics, 105, 295-310.
  96. Andrews AP, Hartnett ME, Hirose T (1999). Surgical advances in retinopathy of prematurity. Int Ophthalmol Clin, 39(1), 275-90. (Read full article)
  97. Sheindlin JA, Hirose T, Hartnett ME (1999). Ophthalmic endoscopy: applications in intraocular surgery. Int Ophthalmol Clin, 39(1), 237-47. (Read full article)
  98. Remky A, Beausencourt E, Hartnett ME, Trempe CL, Arend O, Elsner AE (1999). Infrared imaging of cystoid macular edema. Graefes Arch Clin Exp Ophthalmol, 237(11), 897-901. (Read full article)
  99. Hartnett ME, Garcia CM, DAmore PA (1999). Release of bFGF, an endothelial cell survival factor, by osmotic shock. Invest Ophthalmol Vis Sci, 40(12), 2945-51. (Read full article)
  100. Kunze C, Elsner AE, Beausencourt E, Moraes L, Hartnett ME, Trempe CL (1999). Spatial extent of pigment epithelial detachments in age-related macular degeneration. Ophthalmology, 106(9), 1830-40. (Read full article)
  101. Hartnett ME, Hirose T (1998). Cyanoacrylate glue in the repair of retinal detachment associated with posterior retinal breaks in infants and children. Retina, 18(2), 125-9. (Read full article)
  102. Armstrong D, Ueda T, Ueda T, Aljada A, Browne R, Fukuda S, Spengler R, Chou R, Hartnett M, Buch P, Dandona P, Sasisekharan R, Dorey CK (1998). Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor. Angiogenesis, 2(1), 93-104. (Read full article)
  103. Beausencourt E, Elsner AE, Hartnett ME, Trempe CL (1997). Quantitative analysis of macular holes with scanning laser tomography. Ophthalmology, 104(12), 2018-29. (Read full article)
  104. Armstrong D, Ueda To, Ueda Ta, Browne R, Al-Jada A, Spengler R, Chou R, Fukuda S, Buch P, Dandona P, Hartnett ME, Sasisekharan R, Dorey KC (1997). Expression of TNF-alpha and VEGF during retinal neovascularization is initiated by lipid hydroperoxide. Angiogenesis, 2, 174-84.
  105. Hartnett ME, Weiter JJ, Staurenghi G, Elsner AE (1996). Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology, 103(12), 2042-53. (Read full article)
  106. Steidl SM, Hirose T, Sang D, Hartnett ME (1996). Difficulties in excluding the diagnosis of retinoblastoma in cases of advanced Coats' disease: a clinicopathologic report. Ophthalmologica, 210(6), 336-40. (Read full article)
  107. Hartnett ME, Elsner AE (1996). Characteristics of exudative age-related macular degeneration determined in vivo with confocal and indirect infrared imaging. Ophthalmology, 103(1), 58-71. (Read full article)
  108. Steidl S, Hirose T, Hartnett ME (1995). Open-sky vitrectomy for posterior segment reconstruction in eyes with severe trauma. Int Ophthalmol Clin, 35(1), 175-80. (Read full article)
  109. Hartnett ME, Pruett RC, DaSilva KC, Burkart PT (1994). Antiphospholipid antibody syndrome associated with microscotomata. Am J Ophthalmol, 118(3), 397-8. (Read full article)
  110. Hartnett ME, Katsumi O, Hirose T, Richardson TM, Walton DS (1994). Improved visual function in retinopathy of prematurity after lowering high intraocular pressure. Am J Ophthalmol, 117(1), 113-5. (Read full article)
  111. Hartnett ME, Coles WH (1993). Lens clarity after vitrectomy in traumatic lens perforation and vitreous penetration. Am J Ophthalmol, 116(2), 250-1. (Read full article)
  112. Hartnett ME, Gilbert MM, Hirose T, Richardson TM, Katsumi O (1993). Glaucoma as a cause of poor vision in severe retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol, 231(8), 433-8. (Read full article)
  113. Hartnett ME, Hirose T, Richardson TM, Garsd A, Gilbert MM, Krug J Jr (1992). Intraocular pressure determination in infants with severe retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol, 230(5), 406-10. (Read full article)
  114. Hartnett ME, Weiter JJ, Garsd A, Jalkh AE (1992). Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol, 230(1), 11-9. (Read full article)
  115. Hartnett ME, Gilbert MM, Richardson TM, Krug JH Jr, Hirose T (1990). Anterior segment evaluation of infants with retinopathy of prematurity. Ophthalmology, 97(1), 122-30. (Read full article)
  116. Lazarus HM, Hartnett ME, Reed MD, Murphy BF, Lass JH (1987). Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis. Am J Ophthalmol, 104(5), 476-80. (Read full article)
  117. Mangan KF, Hartnett ME, Matis SA, Winkelstein A, Abo T (1984). Natural killer cells suppress human erythroid stem cell proliferation in vitro. Blood, 63(2), 260-9. (Read full article)
  118. Krohel GB, Tobin DR, Hartnett ME, Barrows NA (1982). Divergence paralysis. Am J Ophthalmol, 94(4), 506-10. (Read full article)

Edited Book

  1. Hartnett ME, ed-in-chief (Eds.) (2005). Pediatric Retina, 1st Edition. Philadelphia, PA: Lippincott Williams & Wilkins.
  2. Steidl S, Hartnett ME (Eds.) (2003). Clinical Pathways in Vitreoretinal Disease. New York, NY: Thieme Publishers.
  3. Schepens CL, Hartnett ME, Hirose T (Eds.) (2000). Schepens’ Retinal Detachment and Allied Diseases. (2nd edition). Boston, MA: Butterworth-Heinemann.